Thompson Andrew J, Verheij Mark H P, Verbeek Joost, Windhorst Albert D, de Esch Iwan J P, Lummis Sarah C R
Department of Biochemistry, University of Cambridge, Cambridge, UK.
Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Sciences, VU University Amsterdam, Amsterdam, The Netherlands.
Neuropharmacology. 2014 Nov;86:378-88. doi: 10.1016/j.neuropharm.2014.08.008. Epub 2014 Aug 28.
VUF10166 (2-chloro-3-(4-methyl piperazin-1-yl)quinoxaline) is a ligand that binds with high affinity to 5-HT3 receptors. Here we synthesise [(3)H]VUF10166 and characterise its binding properties at 5-HT3A and 5-HT3AB receptors. At 5-HT3A receptors [(3)H]VUF10166 displayed saturable binding with a Kd of 0.18 nM. Kinetic measurements gave monophasic association (6.25 × 10(7) M(-1) min(-1)) and dissociation (0.01 min(-1)) rates that yielded a similar Kd value (0.16 nM). At 5-HT3AB receptors two association (6.15 × 10(-7), 7.23 M(-1) min(-1)) and dissociation (0.024, 0.162 min(-1)) rates were seen, yielding Kd values (0.38 nM and 22 nM) that were consistent with values obtained in saturation (Kd = 0.74 nM) and competition (Ki = 37 nM) binding experiments respectively. At both receptor types, specific binding was inhibited by classical 5-HT3 receptor-selective orthosteric ligands (5-HT, allosetron, d-tubocurarine, granisetron, mCPBG, MDL72222, quipazine), but not by non-competitive antagonists (bilobalide, ginkgolide B, picrotoxin) or competitive ligands of other Cys-loop receptors (ACh, bicuculline, glycine, gabazine). To explore VUF10166 ligand-receptor interactions we used in silico modelling and docking, and tested the predictions using site directed mutagenesis. The data suggest that VUF10166 adopts a similar orientation to 5-HT3 receptor agonists bound in AChBP (varenicline) and 5HTBP (5-HT) crystal structures.
VUF10166(2-氯-3-(4-甲基哌嗪-1-基)喹喔啉)是一种与5-HT3受体具有高亲和力结合的配体。在此,我们合成了[³H]VUF10166,并表征了其在5-HT3A和5-HT3AB受体上的结合特性。在5-HT3A受体上,[³H]VUF10166表现出可饱和结合,解离常数(Kd)为0.18 nM。动力学测量给出单相结合(6.25×10⁷ M⁻¹ min⁻¹)和解离(0.01 min⁻¹)速率,得出相似的Kd值(0.16 nM)。在5-HT3AB受体上观察到两种结合(6.15×10⁻⁷,7.23 M⁻¹ min⁻¹)和解离(0.024,0.162 min⁻¹)速率,产生的Kd值(0.38 nM和22 nM)分别与饱和(Kd = 0.74 nM)和竞争(Ki = 37 nM)结合实验中获得的值一致。在这两种受体类型中,特异性结合均受到经典的5-HT3受体选择性正构配体(5-HT、阿洛司琼、d-筒箭毒碱、格拉司琼、mCPBG、MDL72222、喹哌嗪)的抑制,但不受非竞争性拮抗剂(白果内酯、银杏内酯B、印防己毒素)或其他半胱氨酸环受体的竞争性配体(乙酰胆碱、荷包牡丹碱、甘氨酸、gabazine)的抑制。为了探索VUF10166配体与受体的相互作用,我们使用了计算机模拟和对接,并通过定点诱变测试了这些预测。数据表明,VUF10166与结合在乙酰胆碱结合蛋白(伐尼克兰)和5-羟色胺结合蛋白(5-HT)晶体结构中的5-HT3受体激动剂具有相似的取向。